p15-deoxyspergualin, anti-T-cell antibody, corticosteriod, azathioprine, methotrexate or a compound of the formula (I) or (II)



(I)



(II)

[and/or] <u>or</u> an optionally stereoisomeric form of the compound of the formula I or II and/or a physiologically tolerable salt of the compound of the formula I[, is employed where] wherein:

R^1 is a) $(C_1\text{-}C_4)$-alkyl,

b) $(C_3\text{-}C_5)$-cycloalkyl,

c) $(C_2\text{-}C_6)$-alkenyl or

d) $(C_2\text{-}C_6)$-alkynyl,

R^2 is a) $-CF_3$,

b) $-O\text{-}CF_3$,

LAW OFFICES
FINNEGAN, HENDERSON, FARABOW, GARRETT, & DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

c) $-S-CF_3$,

d) -OH,

e) $-NO_2$,

f) halogen,

g) benzyl,

h) phenyl,

i) -O-phenyl,

k) -CN or

l) -O-phenyl, mono- or polysubstituted by

1) (C_1-C_4)-alkyl,

2) halogen,

3) $-O-CF_3$ or

4) $-O-CH_3$,

R^3 is a) (C_1-C_4)-alkyl,

b) halogen, or

c) a hydrogen atom, and

X is a) a -CH group or

b) a nitrogen atom[,] .

[for the production of a pharmaceutical for increasing the tolerance of a mammal, in particular man, to transgenic cells, after discontinuing the immunosuppressant concomitant therapy, the transgenic cells being transfected by means of a recombinant adenovirus vector.]

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

2. (Amended). The [use] method as claimed in claim 1, wherein the pharmaceutical comprises the compound of the formula I and/or II [and/or] or an optionally stereoisomeric form of the compound of the formula I or II and/or a salt of the compound of the formula I [is employed, where] wherein

R^1 is a) methyl,

b) cyclopropyl or

c) $(C_3$-$C_5)$-alkynyl,

R^2 is $-CF_3$ or -CN,

R^3 is a hydrogen atom or methyl, and

X is a -CH group.

3. (Amended). The [use] method as claimed in claim [1 or] 2, wherein the pharmaceutical comprises

N-(4-trifluoromethylphenyl)-5-methylisoxazole-4-carboxamide,

N–(4-trifluoromethylphenyl)-2-cyano-3-hydroxycrotonamide,

2-cyano-3-cyclopropyl-3-hydroxy acrylic acid (4-cyanophenyl)amide or

N-(4-trifluoromethylphenyl)-2-cyano-3-hydroxyhept-2-en-6-ynecarboxamide [is employed].

4. (Amended). The [use] method as claimed in [at least one of claims 1 to 3] claim 1, wherein the pharmaceutical or the pharmaceutical combination is

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

administered ~~before~~, during and/or after the administration of the transgenic cells produced in vitro or [of the] in-vivo [production of the ~~transgenic cells~~].

5. (Amended). The [use] method as claimed in [one of the claims 1 to 4] claim 1, wherein the transgenic cells are produced in the course of a gene therapy treatment.

6. (Amended). The [use] method as claimed in claim 5, wherein the gene therapy treatment is employed for the treatment of all disorders in which a protein or peptide is not produced, is produced inadequately, or only produced defectively in the body of the mammal[, in particular of man].

7. (Amended). The [use] method as claimed in claim 5, wherein the gene therapy treatment is employed for the treatment of hereditary disorders such as cystic fibrosis, familial hypercholesterolemia, hemophilia, sickle cell anemia; of nerve and brain disorders such as Parkinson's, Alzheimer's or Kreuzfeld-Jakob syndrome; of rheumatic disorders, osteoarthritis, osteoporosis or arthrosis, of phenylketonuria; of metabolic disorders, [such as diabetes]; of inflammations; of carcinomatous disorders; of infectious disorders; [,for example AIDS or hepatitis] or of hormone and growth disorders.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000

8. (Amended). The [use] method as claimed in claim 5, wherein the gene therapy treatment is employed in order to generate a vaccine protection against disease pathogens such as viruses, bacteria, fungi, mono- and multicellular parasites and also against abnormal body cells such as tumor cells.

Sub B3

9. (Amended). The [use] method as claimed in [at least one of claims 1 to 8] claim 1, wherein the pharmaceutical or the pharmaceutical combination is administered orally, intravenously, subcutaneously, intraperitoneally, percutaneously, cutaneously, topically, by inhalation, intramuscularly, intrathecally, intraocularly, ocularly, buccally, nasally or rectally[, preferably intravenously or orally].

Please add new claims 10 -13:

Sub B4

--10. The method as claimed in claim 9, wherein the pharmaceutical or the pharmaceutical combination is administered orally or intravenously.

A2

11. The method as claimed in claim 1, wherein the mammal is man.

12. The method as claimed in claim 1, wherein the transgenic cells are transfected by means of a recombinant adenovirus vector.

13. The method of claim 6, wherein the mammal is man.

LAW OFFICES
FINNEGAN, HENDERSON,
FARABOW, GARRETT,
& DUNNER, L.L.P.
1300 I STREET, N. W.
WASHINGTON, D. C. 20005
202-408-4000